Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

Neurocrine Biosciences (NBIX) announced it has amended its agreement with Takeda (TAK) to develop and commercialize osavampator. Under the ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.